Cover Image
市場調查報告書

子宮肌瘤(Uterine leiomyoma) - 開發平台分析

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 234336
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
子宮肌瘤(Uterine leiomyoma) - 開發平台分析 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 89 Pages
簡介

子宮肌瘤是發生在子宮的良性腫瘤。雖然肌瘤和子宮壁(子宮平滑肌)一樣是平滑纖維,但卻較正常子宮肌層更厚,一般呈球型腫塊。子宮肌瘤最常見的症狀有嚴重的月經出血,月經持續七天以上,骨盤壓或疼痛、頻尿、排尿障礙、便秘及背部疼痛和下肢痛等。

本報告提供子宮肌瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等,以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

子宮肌瘤概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Euroscreen S.A.
  • Takeda Pharmaceutical Company Limited
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Kissei Pharmaceutical Co., Ltd.
  • Bayer AG
  • BioSpecifics Technologies Corp.
  • Repros Therapeutics Inc.
  • Dongkook Pharmaceutical Co., Ltd.
  • HRA Pharma
  • AbbVie Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ulipristal acetate
  • relugolix
  • elagolix sodium
  • telapristone acetate
  • mifepristone
  • KLH-2109
  • vilaprisan
  • ESN-364
  • LFA-102
  • collagenase clostridium histolyticum
  • GnRH Antagonists
  • EVE-104
  • triptorelin pamoate biosimilar
  • Drug to Activate Progesterone Receptor for Uterine Fibroids
  • Drugs for Women Health

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9012IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying your bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uterine Leiomyoma (Uterine Fibroids) - Overview
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Addex Therapeutics Ltd
    • Bayer AG
    • BioSpecifics Technologies Corp
    • Dongkook Pharmaceutical Co Ltd
    • Kissei Pharmaceutical Co Ltd
    • Laboratoire HRA Pharma
    • Ogeda SA
    • Repros Therapeutics Inc
    • Takeda Pharmaceutical Company Ltd
  • Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
    • collagenase clostridium histolyticum - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elagolix sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVE-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fezolinetant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KLH-2109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relugolix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telapristone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulipristal acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vilaprisan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPEA-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
  • Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2017: FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex in the Treatment of Uterine Fibroids
      • Jan 25, 2017: Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
      • Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
      • Dec 12, 2016: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Symptomatic Uterine Fibroids
      • Nov 21, 2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment
      • Nov 14, 2016: Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex Delivered Orally and Vaginally for the Treatment of Uterine Fibroids
      • Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City
      • Oct 13, 2016: Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM
      • Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
      • May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
      • May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
      • May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
      • Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
      • Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
      • Dec 21, 2015: Repros Updates Proellex Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2017
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top